Cancer treatment monitoring using cell-free DNA fragmentomes

Circulating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to de...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature communications 2024-10, Vol.15 (1), p.8801-12, Article 8801
Hauptverfasser:	van ’t Erve, Iris, Alipanahi, Bahar, Lumbard, Keith, Skidmore, Zachary L., Rinaldi, Lorenzo, Millberg, Laurel K., Carey, Jacob, Chesnick, Bryan, Cristiano, Stephen, Portwood, Carter, Wu, Tony, Peters, Erica, Bolhuis, Karen, Punt, Cornelis J. A., Tom, Jennifer, Bach, Peter B., Dracopoli, Nicholas C., Meijer, Gerrit A., Scharpf, Robert B., Velculescu, Victor E., Fijneman, Remond J. A., Leal, Alessandro
Format:	Artikel
Sprache:	eng
Schlagworte:	45/23 631/67/1857 692/53/2421 Aged Biomarkers, Tumor - genetics Cancer Cancer therapies Cell-Free Nucleic Acids - blood Cell-Free Nucleic Acids - genetics Circulating Tumor DNA - blood Circulating Tumor DNA - genetics Circulation Colorectal Neoplasms - genetics Colorectal Neoplasms - mortality Deoxyribonucleic acid DNA DNA sequencing Female Gene sequencing Humanities and Social Sciences Humans Lung cancer Lung Neoplasms - genetics Lung Neoplasms - mortality Male Middle Aged Monitoring multidisciplinary Mutation Neoplasms - genetics Neoplasms - mortality Neoplasms - therapy Patients Prognosis Science Science (multidisciplinary) Survival Telemedicine Tumors Whole genome sequencing Whole Genome Sequencing - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Circulating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction and validate the method in two independent cohorts of patients with colorectal or lung cancer. DELFI-TF scores strongly correlate with circulating tumor DNA levels (ctDNA) (r = 0.90, p
ISSN:	2041-1723 2041-1723
DOI:	10.1038/s41467-024-53017-7